Endpoint Health

Endpoint Health, a company based in Palo Alto, California, addresses urgent needs in immune-driven critical and chronic illnesses, such as sepsis and acute respiratory distress syndrome (ARDS), by delivering integrated therapies that are personalized to each patient's biology. The company's intention is to combine novel and on-market therapeutics, companion diagnostics, and artificial intelligence (AI) into an integrated platform designed to improve outcomes in critically ill patients.

The company aims to use AI and integrated data to identify subgroups of critically ill patients that could benefit from specific therapeutics, which are either existing or repurposed drugs. The idea is to give clinicians a better arsenal of therapies with which to treat patients and make better treatment decisions, as clinicians have little time to make treatment decisions and tailor the treatment for the individual patient needs.By creating an integrated platform, Endpoint can easily access, analyze, and then create personalized treatment approaches.

Endpoint Health uses AI techniques to analyze digital (EHR) and molecular data (RNA, proteins, etc.) from critically ill patients to deeply understand their biology, how distinct subgroups of patients may respond to various novel and routine therapies, and to design blood tests and electronic algorithms that could rapidly identify these subgroups and thus potentially be used by physicians as companion diagnostics to target new therapies as well as routine care choices.

Their process then is to identify pharma companies that own rights to new therapies the research process has identified as having high potential to improve patient outcomes. These therapies are often in clinical development for other applications outside of critical illness. They then enter in-licensing or co-development partnerships and use their companion diagnostic products in clinical trials to target the candidate therapies to critically ill patients that are likely to respond positively. Then, if the trials are successful, the companion diagnostics and therapies would both be approved for use as an integrated product—a "targeted therapy" for sepsis or ARDS, for example. Their goal is to bring multiple targeted therapies to market and to personalize how current routine care is delivered for critically ill patients.

Endpoint Health was founded in 2018 by an executive team including the co-founders of GeneWEAVE, an

infection detection and therapy guidance company that was acquired by Roche in a 2015 deal valued at $425 million.The company has received $12 million in debt and equity financing from top-tier investors, including Mayfeld Fund, Y Combinator, AME Cloud Ventures, and Wireframe Ventures. The company is collaborating with more than forty top US and international hospitals with a focus on bringing targeted therapies for critically ill patients.